Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

395
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to comment on "CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy".

European journal of clinical pharmacology·2026
Same author

Bereaved Caregiver Perspectives on Quality of Care at the End of Life Among Adolescents and Young Adults with Cancer.

Journal of palliative medicine·2026
Same author

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

European heart journal·2026
Same author

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy.

European journal of clinical pharmacology·2026
Same author

Hidden in the Septopulmonary Bundle: An Unusual Mechanism of LA Flutter After PFA of the Posterior Left Atrium.

JACC. Clinical electrophysiology·2026
Same author

Diagnostic and Prognostic Performance of Pericoronary Adipose Tissue Attenuation in Suspected Acute Coronary Syndrome: Insights from the RAPID-CTCA Trial.

Radiology. Cardiothoracic imaging·2026
Same journal

Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Implantation: A Bayesian Meta-Analysis of Randomized Controlled Trials.

The Canadian journal of cardiology·2026
Same journal

Practical approach to the assessment of technical scanning skills in transthoracic echocardiography.

The Canadian journal of cardiology·2026
Same journal

Cost-effectiveness of Pharmacist- and Nurse Practitioner-led Medication Management for Heart Failure With Reduced Ejection Fraction.

The Canadian journal of cardiology·2026
Same journal

Rethinking Pacing After Transcatheter Aortic Valve Implantation to Preserve Ventricular Function.

The Canadian journal of cardiology·2026
Same journal

High Intensity Interval Training Versus Moderate Continuous Training in Adults with Congenital Heart Disease: A Randomized Controlled Trial.

The Canadian journal of cardiology·2026
Same journal

Four-Chamber Myocardial Strain to Predict Mortality in Pulmonary Embolism.

The Canadian journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K

Interventions in Hypertrophic Obstructive Cardiomyopathy.

Wern Yew Ding1, Mohammed N Meah2, Rodney Stables2

  • 1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom.

The Canadian Journal of Cardiology
|December 9, 2023
PubMed
Summary
This summary is machine-generated.

Obstructive hypertrophic cardiomyopathy (oHCM) management is complex. This review details current and emerging percutaneous and surgical treatments for oHCM patients, aiming to clarify therapeutic options.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.3K

Related Experiment Videos

Last Updated: Jul 9, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.3K

Area of Science:

  • Cardiology
  • Genetics
  • Interventional Cardiology

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) is the most common inherited cardiomyopathy.
  • oHCM leads to substantial morbidity and mortality.
  • Current oHCM management strategies are not well-defined compared to other cardiac conditions.

Purpose of the Study:

  • To review established and novel therapeutic interventions for obstructive hypertrophic cardiomyopathy.
  • To focus on percutaneous and surgical treatment modalities for oHCM.

Main Methods:

  • Literature review of established and novel interventions for oHCM.
  • Discussion of surgical myectomy, mitral valve procedures, and percutaneous septal ablation.
  • Exploration of device-based therapies and catheter ablation techniques.

Main Results:

  • Surgical myectomy and mitral valve interventions are key surgical options.
  • Percutaneous alcohol septal ablation and septal embolization are discussed.
  • Radiofrequency ablation techniques, including percutaneous intramyocardial septal ablation, are reviewed.

Conclusions:

  • A comprehensive range of percutaneous and surgical options exist for oHCM.
  • Further research is needed to refine management guidelines for oHCM.
  • Optimizing treatment strategies is crucial for improving outcomes in oHCM patients.